2022年全球新冠肺炎疫苗和药物研究热点回眸

新冠肺炎疫情给人类生活带来极大影响。疫情发生后,全球科研机构和制药公司迅速应对,加紧研发疫苗和抗病毒药物。2022年,多个mRNA创新性疫苗、抗病毒中和抗体、小分子抗病毒药物等相继问世。然而,随着多种新冠病毒变异株的相继出现,新冠肺炎疫苗、中和抗体以及小分子药物的有效性大幅降低,不断对新冠肺炎疫苗和药物的开发提出新的挑战。结合文献和商业数据库信息,对当前新冠肺炎疫苗和药物的研发进展进行综述。截至2022年11月,全球已批准或EUA疫苗和药物各30余款,多款疫苗和药物处于临床试验中,中国在新冠疫苗和抗新冠药物研发方面走在世界前列。

Research progress of global COVID-19 vaccines and drugs in 2022

COVID-19 has a great impact on human life. After the outbreak of the epidemic, global scientific research institutions and pharmaceutical companies responded quickly and stepped up the research and development of vaccines and antiviral drugs. A series of therapies such as innovative mRNA vaccines, antiviral neutralizing antibodies, and small molecule antiviral drugs emerged. However, with the emergence of a variety of COVID-19 variants, the effectiveness of COVID-19 vaccines, neutralizing antibody and small molecule drugs greatly reduced, which constantly posed new challenges to the development of COVID-19 vaccines and drugs. This article reviews the research and development progress of COVID-19 vaccines and drugs based on literature and commercial database information. By Nov 2022, there had been more than 30 COVID-19 vaccines and more than 30 anti COVID-19 drugs approved or granted EUA, and many vaccines and drugs in clinical trials. China led the world in the research and development of COVID-19 vaccines and anti COVID-19 drugs.